10-K: Fennec Pharmaceuticals Reports Strong 2023 Results and Secures European Licensing Deal

Fennec Pharmaceuticals announced positive full-year 2023 financial results, highlighted by $21.3 million in PEDMARK net product sales and a significant licensing agreement for European commercialization.

Summary

• Fennec Pharmaceuticals reported full-year 2023 net product sales of $21.3 million for PEDMARK, including $9.7 million in the fourth quarter.
• The company secured an exclusive licensing agreement with Norgine for PEDMARQSI in Europe, Australia, and New Zealand, receiving approximately $43 million upfront.
• The Norgine deal includes potential for up to $230 million in additional commercial and regulatory milestone payments, plus tiered royalties up to the mid-twenties.
• Fennec's cash and cash equivalents were $13.2 million as of December 31, 2023, with a pro forma cash balance exceeding $55 million after the Norgine deal.
• The company's net loss for 2023 was $16.0 million, or $0.60 per share, compared to a net loss of $23.7 million, or $0.90 per share, in 2022.
• Research and development expenses decreased to $0.1 million in 2023 from $3.5 million in 2022, reflecting the shift to commercialization.
• Selling and marketing expenses increased to $12.1 million in 2023, up from $2.8 million in 2022, due to the commercial launch of PEDMARK.
• General and administrative expenses were $20.6 million in 2023, compared to $17.7 million in 2022.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong sales growth, a significant licensing deal, and a reduction in net loss. The company's financial position has been strengthened, and there is a clear path for future growth. However, the company is still operating at a loss and has a significant debt load.

Positives

• PEDMARK sales showed strong growth in its first full year of commercial availability.
• The licensing agreement with Norgine significantly strengthens Fennec's financial position.
• The company has secured regulatory approvals for PEDMARQSI in Europe and the U.K.
• The FDA has reinforced the unique nature of PEDMARK, distinguishing it from other sodium thiosulfate products.
• The company has reduced its net loss compared to the previous year.

Negatives

• The company experienced a net loss of $16.0 million for the year ended December 31, 2023.
• The company's cash and cash equivalents decreased by $10.5 million during 2023.
• Selling and marketing expenses increased significantly due to the commercial launch of PEDMARK.

Risks

• The company's future success depends on the continued commercialization of PEDMARK and PEDMARQSI.
• The company may need to raise additional capital in the future to fund operations and expansion.
• The company faces competition from other pharmaceutical and biotechnology companies.
• The company's financial results may be affected by changes in healthcare spending and policy.
• The company's intellectual property rights may be challenged or infringed upon by third parties.

Future Outlook

Fennec anticipates continued growth in PEDMARK revenues and is focused on expanding its global reach. The company expects the Norgine licensing deal to provide financial stability and support future operations.

Management Comments

• We are pleased with our execution against strategic plans and our momentum in 2023, which sets the stage for further success in 2024 and beyond.
• We have significantly strengthened our balance sheet through the agreement with Norgine, and we remain dedicated to further growing our revenues as we expand the availability of PEDMARK to patients and providers globally.

Industry Context

This announcement reflects the ongoing efforts in the pharmaceutical industry to develop and commercialize treatments for rare diseases and to address unmet medical needs. The licensing agreement with Norgine highlights the importance of strategic partnerships for global market access.

Comparison to Industry Standards

• The revenue growth of PEDMARK in its first full year of commercialization is a positive sign, though it is difficult to compare directly to other companies due to the unique nature of the product and its target market.
• The licensing agreement with Norgine is a common strategy for smaller pharmaceutical companies to expand their reach and commercialize products in international markets, similar to deals made by companies like BioMarin and Ultragenyx.
• The reduction in R&D expenses and increase in sales and marketing expenses is typical for a company transitioning from a development stage to a commercial stage, similar to companies like Sarepta Therapeutics and Vertex Pharmaceuticals.
• The company's net loss is still significant, but the decrease from the previous year is a positive trend, which is common for companies in the early stages of commercialization, similar to companies like Global Blood Therapeutics and Alnylam Pharmaceuticals.

Legal Proceedings

• Fennec is involved in ongoing litigation with CIPLA regarding patent infringement.
• Fennec successfully defended its wholly owned U.S. Patent No. 10,792,363 in an inter partes review.

Stakeholder Impact

• Shareholders will benefit from the increased revenue and strengthened financial position.
• Employees will benefit from the company's growth and success.
• Patients will benefit from the increased availability of PEDMARK and PEDMARQSI.
• Healthcare providers will have access to a unique treatment option for cisplatin-induced ototoxicity.

Next Steps

• Fennec will focus on the continued commercialization of PEDMARK in the U.S.
• Norgine will begin commercialization of PEDMARQSI in Europe, Australia, and New Zealand.
• The company will continue to explore strategic collaborations to expand the global reach of PEDMARK.
• The company will continue to monitor and manage its operating expenses.

Key Dates

Keywords

PEDMARK, PEDMARQSI, ototoxicity, cisplatin, licensing agreement, Norgine, commercialization, European Commission, FDA approval, financial results, biopharmaceutical, sodium thiosulfate